Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model

International Journal of Developmental Neuroscience

Volumn 49, Issue , 2016, Pages 67-78

  Gao, Jingquan ^a   Wang, Xuelai ^a   Sun, Hongli ^a   Cao, Yonggang ^a   Liang, Shuang ^a   Wang, Han ^a   Wang, Yanming ^a   Yang, Feng ^b   Zhang, Fengyu ^b   Wu, Lijie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b The Global Clinical and Translational Research Institute   (United States)

Author keywords

Autism; Docosahexaenoic acid (DHA); Hippocampal cell; Learning impairment; Memory impairment; Neuroprotective

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOCOSAHEXAENOIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; SUPEROXIDE DISMUTASE; VALPROIC ACID; ANTICONVULSIVE AGENT; ENOLASE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTISM; CELL DEATH; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; LEARNING DISORDER; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; THERAPY EFFECT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; LEARNING DISORDERS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; AUTISTIC DISORDER; CASPASE 3; CELL DEATH; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; FEMALE; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; LEARNING DISORDERS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; PHOSPHOPYRUVATE HYDRATASE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; VALPROIC ACID;

EID: 84958235698     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2015.11.006     Document Type: Article

References (59)

1. Agostoni C., Riva E., Trojan S., Bellù R., Giovannini M. Docosahexaenoic acid status and developmental quotient of healthy term infants. Lancet 1995, 346:638.
2. Al-Farsi Y.M., Waly M.I., Deth R.C., Al-Sharbati M.M., Al-Shafaee M., Al-Farsi O., Al-Khaduri M.M., Al-Adawi S., Hodgson N.W., Gupta I., Ouhtit A. Impact of nutrition on serum levels of docosahexaenoic acid among Omani children with autism. Nutrition 2013, 29:1142-1146.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, 50-59. American Psychiatric Association, Washington, DC. 5th ed.
4. Arsenault D., Julien C., Tremblay C., Calon F. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS One 2011, 6:e17397.
5. Bauman M.L., Kemper T.L. Neuroanatomic observations of the brain in autism: a review and future directions. Int. J. Dev. Neurosci. 2005, 23:183-187.
6. Bekaroğlu M., Asian Y., Gedik Y., Değer O., Mocan H., Erduran E., Karahan C. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J. Child Psychol. Psychiatry 1996, 37:225-227.
7. Bennetto L., Pennington B.F., Rogers S.J. Intact and impaired memory functions in autism. Child Dev. 1996, 67:1816-1835.
8. CDC (2012) Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 61, 1-19.
9. Colangelo L.A., He K., Whooley M.A., Daviglus M.L., Liu K. Higher dietary intake of long-chain ω-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009, 25:1011-1019.
10. Das U.N. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevents schizophrenia in adult life?. Med. Sci. Monit. 2004, 10:Hy33-Hy37.
11. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
12. Duong T., Robinson H., BADG, Ritvo A. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am. J. Psychiatry 1986, 143:862-866.
13. Ebert D.H., Greenberg M.E. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013, 493:327-337.
14. Edgin J.O., Pennington B.F. Spatial cognition in autism spectrum disorders: superior, impaired, or just intact?. J. Autism Dev. Disord. 2005, 35:729-745.
15. Emsley R., Oosthuizen P., van Rensburg S.J. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003, 17:1081-1091.
16. Erhardt J.A., Ohlstein E.H., Toomey J.R., Gabriel M.A., Willette R.N., Yue T.-L., Barone F.C., Parsons A.A. Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb. Res. 2001, 103:143-148.
17. Fatemi S., Earle J., McMenomy T. Hippocampal CA4 reelin-positive neurons. Mol. Psychiatry 2000, 5:571.
18. Fatemi S.H., Snow A.V., Stary J.M., Araghi-Niknam M., Reutiman T.J., Lee S., Brooks A.I., Pearce D.A. Reelin signaling is impaired in autism. Biol. Psychiatry 2005, 57:777-787.
19. Fedorova I., Salem N. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukotri. Essent. Fatty Acids 2006, 75:271-289.
20. Foley A.G., Gannon S., Rombach-Mullan N., Prendergast A., Barry C., Cassidy A.W., Regan C.M. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012, 63:750-760.
21. Ghezzo A., Visconti P., Abruzzo P.M., Bolotta A., Ferreri C., Gobbi G., Malisardi G., Manfredini S., Marini M., Nanetti L., Pipitone E., Raffaelli F., Resca F., Vignini A., Mazzanti L. Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features. PLoS One 2013, 8:e66418.
22. Green P., Glozman S., Kamensky B., Yavin E. Developmental changes in rat brain membrane lipids and fatty acids: the preferential prenatal accumulation of docosahexaenoic acid. J. Lipid Res. 1999, 40:960-966.
23. Horrocks L.A., Farooqui A.A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukotri. Essent. Fatty Acids 2004, 70:361-372.
24. Johnson C., Handen B., Zimmer M., Sacco K. Polyunsaturated fatty acid supplementation in young children with autism. J. Dev. Phys. Disabil. 2010, 22:1-10.
25. Lauritzen L., Hansen H.S., Jørgensen M.H., Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 2001, 40:1-94.
26. Lee G.Y.-P., Brown L.M., Teyler T.J. The effects of anticonvulsant drugs on long-term potentiation (LTP) in the rat hippocampus. Brain Res. Bull. 1996, 39:39-42.
27. Li J., Liu W., Ding S., Xu W., Guan Y., Zhang J.H., Sun X. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. Brain Res. 2008, 1210:223-229.
28. Lillycrop K.A., Phillips E.S., Jackson A.A., Hanson M.A., Burdge G.C. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J. Nutri. 2005, 135:1382-1386.
29. Maenner M.J., Durkin M.S. Trends in the prevalence of autism on the basis of special education data. Pediatrics 2010, 126:e1018-e1025.
30. Malone J.P. The systems theory of autistogenesis. SAGE Open 2012, 2:25.
31. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 1992, 120:S129-S138.
32. McNamara R.K., Carlson S.E. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukotri. Essent. Fatty Acids 2006, 75:329-349.
33. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 2009, 360:1597-1605.
34. Meguid N.A., Dardir A.A., Abdel-Raouf E.R., Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol. Trace Elem. Res. 2011, 143:58-65.
35. Polleux F., Lauder J.M. Toward a developmental neurobiology of autism. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10:303-317.
36. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E.-B. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
37. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature 1997, 387:773-776.
38. Rees A.-M., Austin M.-P., Owen C., Parker G. Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Res. 2009, 166:254-259.
39. Rogers S.J., Hepburn S.L., Stackhouse T., Wehner E. Imitation performance in toddlers with autism and those with other developmental disorders. J. Child Psychol. Psychiatry 2003, 44:763-781.
40. Rutter M. Autism research: lessons from the past and prospects for the future. J. Autism Dev. Disord. 2005, 35:241-257.
41. Salowitz N.M., Eccarius P., Karst J., Carson A., Schohl K., Stevens S., Van Hecke A.V., Scheidt R.A. Brief report: visuo-spatial guidance of movement during gesture imitation and mirror drawing in children with autism spectrum disorders. J. Autism Dev. Disord. 2013, 43:985-995.
42. Sasaki T., Kitagawa K., Yagita Y., Sugiura S., Omura-Matsuoka E., Tanaka S., Matsushita K., Okano H., Tsujimoto Y., Hori M. Bcl2 enhances survival of newborn neurons in the normal and ischemic hippocampus. J. Neurosci. Res. 2006, 84:1187-1196.
43. Schneider T., Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
44. Sheikh A.M., Malik M., Wen G., Chauhan A., Chauhan V., Gong C.X., Liu F., Brown W.T., Li X. BDNF-Akt-Bcl2 antiapoptotic signaling pathway is compromised in the brain of autistic subjects. J. Neurosci. Res. 2010, 88:2641-2647.
45. Steele S.D., Minshew N.J., Luna B., Sweeney J.A. Spatial working memory deficits in autism. J. Autism Dev. Disord. 2007, 37:605-612.
46. Stone W.L., Ousley O.Y., Littleford C.D. Motor imitation in young children with autism: what's the object?. J. Abnorm. Child Psychol. 1997, 25:475-485.
47. Strickland A.D. Prevention of cerebral palsy, autism spectrum disorder, and attention deficit-Hyperactivity disorder. Med. Hypotheses 2014, 82:522-528.
48. Su H.-M. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J. Nutri. Biochem. 2010, 21:364-373.
49. Takeuchi K., Gertner M.J., Zhou J., Parada L.F., Bennett M.V., Zukin R.S. Dysregulation of synaptic plasticity precedes appearance of morphological defects in a Pten conditional knockout mouse model of autism. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4738-4743.
50. Van Elst K., Bruining H., Birtoli B., Terreaux C., Buitelaar J.K., Kas M.J. Food for thought: Dietary changes in essential fatty acid ratios and the increase in autism spectrum disorders. Neurosci. Biobehav. Rev. 2014, 45:369-378.
51. Vorhees C.V. Teratogenicity and developmental toxicity of valproic acid in rats. Teratology 1987, 35:195-202.
52. Wang Han, Liang Shuang, Wang Maoqing, et al. Potential serum biomarkers from a metabolomics study of autism. J. Psychiatry Neurosci. 2016, 41(January (1)):27-37.
53. Wiest M., German J., Harvey D., Watkins S., Hertz-Picciotto I. Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukotri. Essent. Fatty Acids 2009, 80:221-227.
54. Wu P., Jiang L., Chen H. Sodium valproate at the therapeutic concentration inhibits the induction but not the maintenance phase of long-term potentiation in rat hippocampal CA1 area. Biochem. Biophys. Res. Commun. 2010, 391:582-586.
55. Yamagata Y., Kobayashi S., Umeda T., Inoue A., Sakagami H., Fukaya M., Watanabe M., Hatanaka N., Totsuka M., Yagi T. Kinase-dead knock-in mouse reveals an essential role of kinase activity of Ca2+/calmodulin-dependent protein kinase IIα in dendritic spine enlargement, long-term potentiation, and learning. J. Neurosci. 2009, 29:7607-7618.
56. Yehuda S., Rabinovitz S., Mostofsky D.I. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J. Neurosci. Res. 1999, 56:565-570.
57. Yochum C.L., Dowling P., Reuhl K.R., Wagner G.C., Ming X. VPA-induced apoptosis and behavioral deficits in neonatal mice. Brain Res. 2008, 1203:126-132.
58. Yui K. Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders. Seishin Shinkeigaku Zasshi 2012, 114:934-940.
59. Yui K., Koshiba M., Nakamura S., Onishi M. Therapeutic effects of larger doses of arachidonic acid added to DHA on social impairment and its relation to alterations of polyunsaturated fatty acids in individuals with autism spectrum disorders. Nihon Shinkei Seishin Yakurigaku Zasshi 2011, 31:117-124.